Down syndrome screening test | down syndrome test | Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Down syndrome screening test

Ground-breaking Down Syndrome Screening Tests Rule Out Common Risks

Testing for potential fetal abnormalities is recommended to all expectant parents. The most commonly prescribed procedure is a Down Syndrome diagnostic test, which is usually carried out through amniocentesis. But this procedure is not without risk: while the chances of losing the fetus is small, it remains a concern. In response, Eurofins Biomnis has developed non-invasive genetic tests that deliver fast and accurate results. Their NIPT (non-invasive prenatal testing) kit draws analysis from a maternal blood sample. By choosing our non-invasive Down Syndrome screening test, it can be safely determined whether the risk of fetal defects is high or low, reducing the need for invasive procedures by up to 95%.

Although pregnancy risks are a common topic in popular media, expectant parents are often ill-informed about their screening and assessment options, believing that in order to undergo a Down Syndrome test, they must choose among invasive and potentially risky medical procedures. But while amniocentesis tests for trisomy carry some non-negligible risks, effective non-invasive options are now readily available. By opting for a EurofinsBiomnis NIPT test, you can significantly reduce or eliminate the need for complicated and invasive prenatal screenings. Safe, reliable, and rapid, the Down Syndrome test can be obtained starting in only the tenth week of pregnancy. It simultaneously detects risks for trisomies 13, 18 and 21.

To effectively rule out those risks, scheduling a non-invasive Down Syndrome screening analysis with a primary care physician or other healthcare provider offers patients and expectant parents genuine peace of mind. Non-invasive genetic testing during pregnancy helps patients and practitioners mitigate the risks associated with more traditional prenatal screening procedures. The Down Syndrome screening analysis developed byEurofins Biomnis can be ordered to your physician's practice and carried out there, or at a Eurofins Biomnis partner laboratory. During your consultation, your healthcare provider will prescribe an NIPT and ask you to sign an informed consent form. The procedure is quick and painless, and results are available within about a week.

Can Down Syndrome really be detected prenatally to a high level of accuracy, without relying on invasive testing methods? The answer is yes. The NIPT screening kits developed by Biomnis are remarkably accurate, offering a detection rate of over 99%. This allows healthcare providers to frequently eliminate all need to undergo invasive types of prenatal diagnosis. How does this work? Besides maternal DNA, the blood of pregnant women contains fetal DNA. The NIPT test uses an innovative technology to determine whether a trisomy is present in the fetus. Yes, Down Syndrome can now be detected prenatally, without risk.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%